Clinical Trials Logo

Filter by:
NCT ID: NCT02727049 Withdrawn - Athletic Injuries Clinical Trials

Motion Capture and Analysis of NYIT Athletes

Start date: February 2015
Phase: N/A
Study type: Interventional

The purpose of this research is to: 1. determine the normal or existing dynamic biomechanics of college athletes and 2. test the effectiveness of osteopathic manipulative medicine in the treatment of athletic injuries. Motion capture using Vicon systems allows researchers to quantify characteristics of a body such as the range of motion of the hip or shoulder during an athletic technique such as kicking or shooting a basketball into the basket. The quantified information has been used before to better understand human mobility and performance. Osteopathic manipulative medicine (OMM) is manual medicine applied to joints, muscles, and connective tissue with a goal of improved body functions. Research demonstrating effectiveness of OMM on the musculoskeletal and associated connective tissue systems health includes, among others, prospective clinical trials of OMM for treatment of neck pain, low back pain, and acute first- and second-degree ankle sprains.

NCT ID: NCT02726867 Withdrawn - Epilepsy Clinical Trials

Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus

Start date: February 2014
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of levetiracetam , lacosamide and ketamine treatment of refractory status epilepticus. This will be a randomized, open-label, four-arm pilot study comparing time to cessation of refractory status epilepticus, determined by continuous EEG monitoring, in patients with refractory status epilepticus. Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical status epilepticus for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) either 4000 mg levetiracetam, 600 mg lacosamide (Group B), 2.5 mg/kg ketamine or phenobarbital 15 mg/kg phenobarbital (Group D)

NCT ID: NCT02726282 Withdrawn - Thyroid Cancer Clinical Trials

Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences: a Cross Sectional Survey

Start date: March 2016
Phase: N/A
Study type: Observational

To explore how a clinical sample of patients with thyroid nodules (men and women) with no history of thyroid cancer would make decisions about treatments based on different terminology used to describe papillary thyroid cancer (with and without the cancer term).

NCT ID: NCT02726191 Withdrawn - Epilepsy Clinical Trials

Computerized Cognitive Training in Epilepsy

Start date: January 2017
Phase: N/A
Study type: Interventional

The purpose of this randomized uncontrolled single-site trial is to evaluate the efficacy of two novel computerized cognitive enhancing software packages for improving cognitive and behavioral outcomes in patients with epilepsy.

NCT ID: NCT02726139 Withdrawn - Hemophilia A Clinical Trials

Improved Factor VIII Inhibitor Evaluation

IFIE
Start date: July 15, 2016
Phase:
Study type: Observational

Commercial one and two-stage factor VIII assays may not detect some clinically significant inhibitor antibodies. The purpose of the proposed study is to standardize and validate a platelet-based factor VIII activity assay with greater sensitivity to clinically important inhibitory antibodies. Investigators will evaluate the platelet-dependent inhibitory activity vs. conventional inhibitory activity in stored patient plasmas and correlate to bleeding histories

NCT ID: NCT02726035 Withdrawn - Clinical trials for Self-injurious Behavior

Evaluation of Naltrexone as a Treatment for Self-injurious Behavior

NTX-SIB
Start date: February 22, 2014
Phase: Phase 4
Study type: Interventional

The proposed study examines the effect of oral naltrexone on self-injurious behavior (SIB) in adolescents and adults of normal intelligence.

NCT ID: NCT02725658 Withdrawn - Breast Tumor Clinical Trials

Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI

Start date: December 2015
Phase: N/A
Study type: Interventional

The purpose of this research study is to help us learn if an experimental imaging device called Diffuse Optical Spectroscopic Imaging (DOSI) can monitor tumor shrinkage during chemotherapy treatment and can predict if the tumor will respond to chemotherapy before the end of the treatment. This study will also help us understand the biological reason for how DOSI works.

NCT ID: NCT02725541 Withdrawn - Breast Cancer Clinical Trials

Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer

NATURE
Start date: March 2016
Phase: Phase 2
Study type: Interventional

This is an open label, neoadjuvant phase II study to evaluate the objective response, toxicity, and safety of trastuzumab emtansine in patients with newly diagnosed HER2-equivocal breast cancer. Trastuzumab emtansine at a dose of 3.6 mg/kg will be intravenously administered every 3 weeks for a total of 6 weeks. Patients who achieve a partial or complete response after the 6-week treatment (responders) will continue on trastuzumab emtansine for an additional 12 weeks.

NCT ID: NCT02724995 Withdrawn - Rare Diseases Clinical Trials

Finding Genes for Rare Diseases

Start date: February 2016
Phase: N/A
Study type: Observational

This study will help the investigator understand the pathogenesis of different rare genetic conditions and to establish database of rare genetic databases. This would ultimately help to provide more accurate diagnosis through advanced genomic diagnostic testing and databases established from this study. This knowledge would in turn help in the clinical management of other affected family members and other individuals affected with similar conditions. Understanding of pathogenesis of the disease would also enable the investigator to develop targeted therapies for rare genetic diseases, and also to collaborate on the targeted therapy-related clinical trials. The investigator plans to store the results of this study in databases. These results will be shared with other researchers or doctors, who research, diagnose or treat the individuals with similar diseases. The investigator will only share the data that is collected and not the biological samples.

NCT ID: NCT02724904 Withdrawn - Lymphoma Clinical Trials

Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma

Start date: May 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is assessing the feasibility of reduced intensity allogeneic hematopoietic stem cell transplantation (HSCT) as a possible treatment for relapsed / refractory non-Hodgkin lymphoma involving the central nervous system (CNS). HSCT is the transplantation of stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood.